title: The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate.
abstract: BACKGROUND
  This study was designed to determine whether androgen ablation (AA) affects expression of alpha1A-adrenergic receptors (AR) in the human prostate.
  
  
  METHODS
  Concentrations of alpha1A-AR mRNA were determined in benign prostatic tissue from patients undergoing surgery after a 3-month course of combined androgen ablation (CAD) therapy with leuprolide and flutamide, and a matched group of untreated patients with clinical BPH.
  
  
  RESULTS
  Mean concentration of alpha1A-AR in the AA group was 0.53 +/- 0.53 SD (range 0.026-1.55) attomol/mg. Control mean was 0.29 +/- 0.22 SD (range 0.02-0.69; P = 0.3, two tailed t-test). Tissue composition did not statistically differ between the two groups. Expression of alpha1A-AR correlated with concentration of smooth muscle myosin heavy chain (SMMHC) (r = 0.84, P = 0.001). No significant differences were observed after adjusting for SMMHC content.
  
  
  CONCLUSIONS
  A 3-month course of CAD does not appear to have a significant effect on alpha1A-AR mRNA expression in the human prostate.
authors.affiliation: Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Elie.Benaim@UTSouthwestern.edu
authors.forename: Elie A
authors.initials: EA
authors.lastname: Benaim
authors.forename: Jose A
authors.initials: JA
authors.lastname: Karam
authors.forename: M Hossein
authors.initials: MH
authors.lastname: Soboorian
authors.forename: Claus G
authors.initials: CG
authors.lastname: Roehrborn
authors.forename: John D
authors.initials: JD
authors.lastname: McConnell
authors.forename: Victor
authors.initials: V
authors.lastname: Lin
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000494:pharmacology*; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D005485:Flutamide / Q000494:pharmacology; D006801:Humans; D016729:Leuprolide / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012333:RNA, Messenger / Q000032:analysis; D018340:Receptors, Adrenergic, alpha-1 / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: C547713:ADRA1A protein, human; D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D012333:RNA, Messenger; D018340:Receptors, Adrenergic, alpha-1; D005485:Flutamide; D016729:Leuprolide